Business Description
ArriVent BioPharma Inc
NAICS : 541714
SIC : 2834
ISIN : US04272N1028
Total Employee Number:
77Description
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 778.95 | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -58.7 | |||||
3-Year EPS without NRI Growth Rate | -55.2 | |||||
3-Year FCF Growth Rate | -45.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.64 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.77 | |||||
9-Day RSI | 42.05 | |||||
14-Day RSI | 49.98 | |||||
3-1 Month Momentum % | 10.49 | |||||
6-1 Month Momentum % | 35.91 | |||||
12-1 Month Momentum % | 39.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.95 | |||||
Quick Ratio | 13.95 | |||||
Cash Ratio | 13.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.9 | |||||
Shareholder Yield % | -16.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -52.3 | |||||
ROA % | -48.61 | |||||
ROIC % | -1076.32 | |||||
3-Year ROIIC % | 1987.67 | |||||
ROC (Joel Greenblatt) % | -123134.22 | |||||
ROCE % | -56.47 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.55 | |||||
Price-to-Tangible-Book | 4.55 | |||||
EV-to-EBIT | -7.58 | |||||
EV-to-EBITDA | -7.58 | |||||
EV-to-Forward-Revenue | 6.6 | |||||
EV-to-FCF | -8.85 | |||||
| Price-to-Net-Current-Asset-Value | 4.56 | |||||
| Price-to-Net-Cash | 4.9 | |||||
Earnings Yield (Greenblatt) % | -13.19 | |||||
FCF Yield % | -8.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ArriVent BioPharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.47 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 47.79 | ||
| 14-Day RSI | 49.98 | ||
| 14-Day ATR ($) | 1.571307 | ||
| 20-Day SMA ($) | 33.19525 | ||
| 12-1 Month Momentum % | 39.64 | ||
| 52-Week Range ($) | 16.1 - 35.83 | ||
| Shares Outstanding (Mil) | 46.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ArriVent BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ArriVent BioPharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 27 days | ||
| General meeting for 2026 | 2026-06-18 12:00 | 31.36 (+2.38%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 29.50 (+2.04%) | ||
| Annual report for 2025 | 2026-03-05 | 26.56 (+10.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 26.56 (+10.67%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 18.05 (-1.98%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 17.99 (-3.69%) | ||
| General meeting for 2025 | 2025-06-18 12:00 | 24.98 (-1.19%) | ||
| First quarter earnings results for 2025 | 2025-05-12 | 20.15 (+2.34%) |
Show
Entries
ArriVent BioPharma Inc Frequently Asked Questions
What is ArriVent BioPharma Inc(AVBP)'s stock price today?
The current price of AVBP is $32.54. The 52 week high of AVBP is $35.83 and 52 week low is $16.10.
When is next earnings date of ArriVent BioPharma Inc(AVBP)?
The next earnings date of ArriVent BioPharma Inc(AVBP) is 2026-08-11 Est..
Does ArriVent BioPharma Inc(AVBP) pay dividends? If so, how much?
ArriVent BioPharma Inc(AVBP) does not pay dividend.
Guru Commentaries on NAS:AVBP
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| $207B Market Shift: The Race for Fast Track Approval in Oncology | 2026-02-05 | ||
| Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B | 2025-12-16 |
Articles on ArriVent BioPharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers